By Product Type
By Research Area
A promising target for both diagnosis and therapeutics treatments of the new disease named COVID-19 is the coronavirus (CoV) spike (S) glycoprotein. The spike protein, which is responsible for the “corona” (Latin word for crown) appearance in all coronaviruses, is a type I glycoprotein that has an especial role in the interaction between the virus and the host cell. This protein attaches itself to specific cellular receptors and suffers a conformational change that enables the fusion of the virus and the cell (1). Studies have shown that the SARS-CoV-2’s S RBD protein interacts strongly with the Angiotensin-converting enzyme 2 (ACE2). S-RBD protein in order to enlighten the binding epitopes of these Abs. Because of the conservation of S-RBD protein sequence and its strong immunogenicity, the S-RBD protein of coronavirus is chosen as a diagnostic tool. COVID-19 antibodies can be produced by a host immune system following exposure to SARS-CoV-2. IgG and IgM antibodies are also known as immunoglobulins IgG and IgM, respectively, and are among the antibody isotypes produced by vertebrate immune systems.The ELISA microplate is coated with the SARS-CoV-2 S-RBD protein. The coated S-RBD protein binds with COVID-19 IgG/IgM S-RBD antibodies in the serum sample.